HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Muyuan Foods - The Hog King in China Has Greater Potential and Resilience

Pre-IPO LXJ International Holdings - The Pain Points and the Outlook

Pre-IPO Bama Tea - The Business Model, the Challenges and the Outlook

Pre-IPO Vigonvita Life Sciences - The Challenges Behind the Pipeline and the Outlook

Pre-IPO Foshan Haitian Flavouring & Food Company (PHIP Updates) - Some Points Worth the Attention

Equity Capital Markets

Shenzhen Hipine Precision Technology / Equity Capital Markets

Shenzhen Hipine Precision Technology (HPT HK)

<ul>
<li>Although high gold price helps drive revenue growth as Hipine generally adjusts selling prices, consumer sentiment and demand for purchasing non-essential items such as precious metal watch would be suppressed.</li>
<li>The biggest challenge is that ceiling in gold watch industry is not high. It’s not easy to create new imagination space in a segmented market, which would affect valuation expansion.</li>
<li>Due to the concerns on the future growth potential and profitability, we'e not optimistic about the outlook of Hipine. We think the valuation of Hipine could be lower than peers.</li>
</ul>


Although high gold price helps drive revenue growth as Hipine generally adjusts selling prices, consumer sentiment and demand for purchasing non-essential items such as precious metal watch would be suppressed.
The biggest challenge is that ceiling in gold watch industry is not high. It’s not easy to create new imagination space in a segmented market, which would affect valuation expansion.
Due to the concerns on the future growth potential and profitability, we'e not optimistic about the outlook of Hipine. We think the valuation of Hipine could be lower than peers.


Pre-IPO Shenzhen Hipine Precision Technology (PHIP Updates) - Some Points Worth the Attention